Related Experiment Video
Updated: Aug 29, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Emerging hormonal agents for the treatment of prostate cancer
Emily Bochner1, Sam Gold1, Ganesh V Raj1
1The Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Introduction:
Prostate cancer is the most common solid organ malignancy in men in the United States. Until recently, treatment options for men with metastatic disease were limited and patients faced poor outcomes with minimal alternatives. The landscape of prostate cancer treatment has transformed and taken shape over the last 20 years with novel hormonal and non-hormonal therapeutics that have demonstrated significant improvement in survival. However, patients with advanced disease still face imminent progression on hormone blockade therapy.
Areas Covered:
There is a significant market opportunity to devise novel, more potent agents for patients with hormone-resistant disease. Here we review the existing treatment options in men with advanced prostate cancer, the market opportunity within this field, goals of current research, and the novel agents under investigation, including androgen receptor degraders, testosterone synthesis pathway inhibitors, DNA-binding domain and N-terminal domain antagonists, and the combination of hormonal and non-hormonal agents.
Expert Opinion:
Combination therapy regimens and novel agents targeting alternative binding domains of the androgen receptor are of great interest, as they may overcome resistance mechanisms and hold promise as the future of advanced prostate cancer treatment.
Insights
New treatments offer hope for advanced prostate cancer. Research focuses on novel agents and combination therapies to overcome hormone resistance and improve survival for men with metastatic disease.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Prostate cancer is a leading malignancy in men, with limited options for metastatic disease historically.
- Recent advancements in hormonal and non-hormonal therapies have improved survival, but progression on hormone blockade remains a challenge.
Approach:
- Review of current treatment options for advanced prostate cancer.
- Exploration of market opportunities for novel therapeutics.
- Investigation of emerging agents including androgen receptor degraders, testosterone synthesis inhibitors, and novel antagonists.
Key Points:
- Novel agents targeting alternative androgen receptor binding domains are under investigation.
- Combination therapy regimens show promise in overcoming resistance mechanisms.
- Significant market opportunity exists for developing potent agents for hormone-resistant prostate cancer.
Conclusions:
- Advanced prostate cancer treatment is evolving with new therapeutic strategies.
- Combination therapies and novel agents targeting the androgen receptor represent the future direction.
- Overcoming hormone resistance is crucial for improving outcomes in advanced prostate cancer.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...